My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

549.53 -11.02 (-1.97%)

Streaming Delayed Price Updated: 1:15 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Is Madrigal Pharmaceuticals (MDGL) Stock Up 216% Today? ↗

December 19, 2022

Madrigal Pharmaceuticals (MDGL) stock is rocketing higher on Monday after sharing positive results from its NASH treatment.

Via InvestorPlace

Madrigal Pharma Stock Triples After Knocking NASH Study Out Of The Park ↗

December 19, 2022

The company hit both of its goals in a Phase 3 study of a pill for the liver disease.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 19, 2022

Via Benzinga

Madrigal Shares Skyrocket After Successful NASH Study ↗

December 19, 2022

Via Benzinga

Tesla, Amazon, Madrigal Pharma, Pfizer, Synaptogenix: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

December 18, 2022

Major Wall Street indices had closed in the red on Friday in the wake of a continued sell-off following the hawkish stance asserted by the Federal Reserve. Friday witnessed volatile trading as a large...

Via Benzinga

2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter ↗

November 06, 2022

These two healthcare stocks could deliver market-crushing gains by year's end.

Via The Motley Fool

Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis ↗

June 27, 2022

Via Benzinga

Recap: Madrigal Pharmaceuticals Q1 Earnings ↗

May 09, 2022

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Madrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular Health ↗

January 31, 2022

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has

Via Benzinga

Madrigal Pharmaceuticals: Q3 Earnings Insights ↗

November 03, 2022

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 28, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 25, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022 ↗

July 08, 2022

Via Benzinga

Bear Market Rally Lifts HealthCare Stocks Off Bottom ↗

June 22, 2022

Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.

Via Talk Markets

Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch ↗

May 09, 2022

Via Benzinga

Tough Slogging Ahead for Investors, Diversification is Important ↗

March 07, 2022

Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.

Via Talk Markets

Earnings Scheduled For May 9, 2022 ↗

May 09, 2022

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

Via Benzinga

Madrigal Pharmaceuticals: A "Best in Class" Biotech Buy ↗

February 17, 2022

One of the few broadly positive binary events in biotechnology of late, Madrigal’s best-in-class NASH compound is well on its way with de-risked, late-stage clinical results.

Via Talk Markets

Bear Market Bets In Biotech ↗

February 07, 2022

Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.

Via Talk Markets

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 03, 2022

Gainers SOC Telemed (NASDAQ:TLMD) shares increased by 333.5% to $2.79 during Thursday's regular session. Trading volume for this security as of 12:30 EST is 19.4...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 31, 2022

Gainers Madrigal Pharmaceuticals (NASDAQ:MDGL) shares rose 14.9% to $64.8 during Monday's pre-market session. The market value of their outstanding shares is at $1.1...

Via Benzinga

Top Picks For 2022: Madrigal Pharmaceuticals ↗

January 22, 2022

Madrigal Pharmaceuticals is poised to deliver positive Phase III data in 2022 for resmetirom, its best-in-class NASH (nonalcoholic steatohepatitis) compound.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 ↗

October 07, 2021

Upgrades For State Street Corporation (NYSE:

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗

September 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...

Via Benzinga

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗

September 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗

September 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...

Via Benzinga

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck ↗

August 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.